Provided by Tiger Trade Technology Pte. Ltd.

Novavax

8.94
+0.52006.18%
Post-market: 8.980.0359+0.40%19:59 EDT
Volume:10.45M
Turnover:93.78M
Market Cap:1.47B
PE:-5.89
High:9.20
Open:8.44
Low:8.44
Close:8.42
52wk High:11.97
52wk Low:6.20
Shares:164.43M
Float Shares:143.00M
Volume Ratio:2.21
T/O Rate:7.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5181
EPS(LYR):2.58
ROE:-898.20%
ROA:-6.51%
PB:-7.71
PE(LYR):3.47

Loading ...

Novavax Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 12

Novavax Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Jun 11

Novavax Inc. Stock Sheds 9.2%, Underperforms Peers

Dow Jones
·
Jun 09

Novavax Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Jun 06

Novavax’s Combo COVID-19 and Flu Shot Trial Reaches Key Milestone for Older Adults

TIPRANKS
·
Jun 06

Novavax and Sanofi Advance Omicron JN.1 Booster With Completed Phase 3 Study

TIPRANKS
·
Jun 06

Novavax Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Jun 02

Novavax to present at Jefferies Global Healthcare Conference fireside chat

Reuters
·
Jun 02

Novavax Inc. Stock Rallies 6.3%, Outperforms Peers

Dow Jones
·
May 30

US FDA Advisers Vote in Favor of Recommending Covid Vaccines Target Jn.1 Lineage Xfg Variant for 2026-27 Campaign

THOMSON REUTERS
·
May 29

Stock Track | Novavax Plummets 5.04% Intraday on FDA Vaccine Composition Uncertainty

Stock Track
·
May 28

Sanofi Says Manufacturing Xfg Protein Nuvaxovid Vaccine as Its Single Global Covid-19 Product for the 2026-27 Season: Briefing Docs

THOMSON REUTERS
·
May 28

FDA advisers to weigh composition of COVID vaccines for 2026-2027

Reuters
·
May 28

Novavax Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
May 28

Novavax Inc. Stock Rallies 13.6%, Outperforms Peers

Dow Jones
·
May 27

Stock Track | Novavax Soars 12.54% as FDA Considers XFG-Targeted COVID Vaccine Update

Stock Track
·
May 26

US FDA advisers to weigh updating 2026-27 COVID vaccines to target XFG variant

Reuters
·
May 26

The Bull Case For Novavax (NVAX) Could Change Following Shah Capital’s Activist Governance Challenge - Learn Why

Simply Wall St.
·
May 25

Assessing Novavax (NVAX) Valuation As Shah Capital Challenges Leadership And Sanofi Partnership

Simply Wall St.
·
May 23

Novavax Updates Pediatric COVID-19 Vaccine Trial: What Investors Should Watch

TIPRANKS
·
May 23